A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)

计划入组 80 人 · 首次发布于 2020 年 8 月 28 日

Shapedown BC Program Evaluation

计划入组 119 人 · 首次发布于 2007 年 11 月 28 日

Bladder Shaper Test

计划入组 156 人 · 首次发布于 2019 年 7 月 12 日

HY-209

chaperone therapy (oral, GM1 gangliosidosis)

AlloStim + autologous chaperone protein vaccine

SHAPERON INC.

Japan

Shaperon, Inc.

South Korea

Sharon Walsh

United States

Hudson Therapeutics' Nugel Shows Promise in Phase 2b Trial for Atopic Dermatitis

NuSepin Shows Promise in Suppressing Systemic Inflammatory Response Syndrome After Bypass Surgery

Eyenovia's Phase 3 CHAPERONE Study Fails to Meet Primary Endpoint for Pediatric Myopia